Efficacy of Tyrosine Kinase Inhibitor Therapy in a Chemotherapy-refractory B-cell Precursor Acute Lymphoblastic Leukemia With ZC3HAV1-ABL2 Fusion

Hemasphere. 2019 Jun 4;3(3):e193. doi: 10.1097/HS9.0000000000000193. eCollection 2019 Jun.

Gauthier Decool^{1

2}, Carine Domenech³, Nathalie Grardel¹, Adriana Plesa⁴, Imelda Raczkiewicz¹, Benoit Ducourneau¹, Philippe Ruminy⁵, Marie-Pierre Pages⁴, Sandrine Girard⁴, Laurène Fenwarth^{1

2}, Claude Preudhomme^{1

2}, Yves Bertrand³, Nicolas Duployez^{1

2}

¹ Laboratory of Hematology, Biology and Pathology Center, CHU Lille, Lille, France.
² INSERM UMR-S 1172, Cancer Research Institute, Lille, France.
³ Department of Pediatric Hematology, IHOP, Hospices Civils de Lyon and Claude Bernard University, Lyon, France.
⁴ Laboratory of Hematology, Lyon-Sud Hospital, Hospices Civils de Lyon, Pierre Bénite, France.
⁵ INSERM U918, Centre Henri Becquerel, Institute for Research and Innovation in Biomedicine, Rouen, France.

No abstract available

Publication types